...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >The serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and soluble gp130 (sgp130) in different tumour stages. Correlation between the two parameters in progression of malignancy.
【24h】

The serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and soluble gp130 (sgp130) in different tumour stages. Correlation between the two parameters in progression of malignancy.

机译:在不同肿瘤阶段,可溶性细胞间粘附分子1(SICAM-1)和可溶性GP130(SGP130)的血清水平。 两个参数在恶性肿瘤进展中的相关性。

获取原文
获取原文并翻译 | 示例

摘要

Cell adhesion molecules are cell surface glycoproteins that may act as mediators in the metastatic process. In this study we measured serum levels of the soluble intercellular adhesion molecule-1 (sICAM-1) in 74 patients with various tumours, divided into four groups according to tumour stage and previous therapy. Serum values of sgp130 were determined in the same patients. As controls we took healthy persons (n=18 for sICAM-1; n=28 for sgp130). Two parameters were determined by ELISA. The serum values of sICAM-1 were significantly elevated compared to controls in stages III + IV both without and after previous chemo/radiotherapy (P<0.05). In stages I + II without or with previous therapy there was no significance. The serum values of sgp130 were increased significantly at each tumour stage both without and after therapy. There were significant correlations between the values of sICAM-1 and sgp130 in patients with progression (tumour stage III + IV without therapy P<0.01; after chemo/radiotherapy P<0.05). To our knowledge this relationship between the two serum parameters has never before been reported. The simultaneous measurement of sICAM-1 and sgp130 could be important in the evaluation of the clinical progression of malignant diseases.
机译:细胞粘附分子是细胞表面糖蛋白,可以在转移过程中充当介质。在这项研究中,我们测量了74例患有各种肿瘤患者的可溶性细胞间粘附分子-1(SICAM-1)的血清水平,根据肿瘤期和先前的疗法分为四组。在同一患者中确定SGP130的血清值。作为对照,我们服用了健康的人(SICAM-1 = 18; SGP130的n = 28)。通过ELISA确定两个参数。与先前的化学/放射疗法的III + IV阶段相比,SICAM-1的血清值显着升高(P <0.05)。在I + II阶段,没有或进行先前的治疗,没有意义。在没有治疗后,每个肿瘤阶段的SGP130的血清值都显着增加。 SICAM-1和SGP130的值之间存在显着相关性(肿瘤III期 + IV,没有治疗p <0.01;化学/放射治疗后P <0.05)。据我们所知,这两个血清参数之间的这种关系从未报道过。 SICAM-1和SGP130的同时测量对于评估恶性疾病的临床进展可能很重要。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号